Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997
Quality Assurance Review Center
Health Services Administration | Neoplasms | Oncology | Radiology
BACKGROUND: We reviewed 56 IRS-IV patients with localized rhabdomyosarcoma [RMS] of the retroperitoneum/pelvis to assess outcome and prognostic factors, including the value of initially excising > or=50% of the tumor (debulking) before chemotherapy.
METHODS: Patients had embryonal RMS [N=38], alveolar RMS [N = 7], RMS not otherwise specified [NOS, N = 7], or undifferentiated sarcoma [N = 4]. Fifteen patients were debulked; 41 patients were biopsied. All received VAC; most received radiotherapy.
RESULTS: Estimated 5-year failure-free survival [FFS] and overall survival rates were 70 and 75%, respectively. FFS rates were better for patients /undifferentiated sarcoma. After adjusting for age and histological differences, FFS was better for patients whose tumor was debulked prior to beginning therapy [P = 0.02].
CONCLUSIONS: These results are superior to those of previous protocols for patients with RMS of the retroperitoneum/pelvis. Initial excision of > or=50% of the tumor may be associated with increased FFS.
DOI of Published Version
Pediatr Blood Cancer. 2004 Jun;42(7):618-25. Link to article on publisher's site
Pediatric blood and cancer
Raney RB, Stoner JA, Walterhouse DO, Andrassy RJ, Donaldson SS, Laurie F, Meyer WH, Qualman SJ, Crist WM. (2004). Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997. IROC Rhode Island (QARC) Publications. https://doi.org/10.1002/pbc.20012. Retrieved from https://escholarship.umassmed.edu/qarc/56